Editor’s Letter

40 0

Welcome to the 10th edition of HD Insights, timed for the beginning of CHDI’s 10th Annual HD Therapeutics Conference. We are pleased to continue our mission to promote, disseminate and facilitate research in Huntington disease. We are grateful to the Huntington Study Group (HSG), our sponsors, and our more than 2600 subscribers for their continuing support.

This edition explores several promising areas of current HD research. We discuss the positive results of Auspex Pharmaceuticals’ First-HD trial, which give the HD community hope of a second FDA-approved treatment for HD. We interview Dr. Francesca Cicchetti, whose groundbreaking research was featured in the Insights of the Year competition last fall, and bring you her thoughts on advances in our current understanding of HD and the future of HD research and therapies. Dr. Lise Munsie provides a “round-up” of current basic science and clinical research in HD. Our editorial team examines the use of laquinimod in neurodegenerative disease, which has led to the ongoing LEGATO-HD Phase 2 trial, and brings you the highlights of HSG 2014. Finally, we continue to provide an up-to-date status report on ongoing and recently concluded HD clinical trials.

The HD Insights team continues to rely on the support of firms dedicated to developing novel treatments to support our efforts to reach and educate the international HD research community. If you are interested in becoming a supporter, please contact me at editor@hdinsights.org . We welcome new contributors, suggestions for topics, and ideas about how we can better serve you. If you or someone you know would like to share their ideas with over 2600 HD researchers and clinicians around the world, please contact me at editor@hdinsights.org . Finally, subscription to HD Insights is always free: simply send us an email at subscribe@hdinsights.org.

Dorsey_feat

 

 

 

 

 

 

 

 

Ray Dorsey, MD

Editor, HD INSIGHTSTM

HD DISCLOSURES: DR. DORSEY RECEIVES GRANT SUPPORT FROM AUSPEX PHARMACEUTICALS, THE HUNTINGTON STUDY GROUP, AND PRANA BIOTECHNOLOGY.


Editorial Board Members

Ray Dorsey, MD — Editor, University of Rochester

Donald Kennedy, PhD — Stanford University

Nobuyuki Nukina, MD, PhD — Riken Brain Science Institute

Rodrigo Osorio — Agrupación Chilena de Huntington

Bernard Ravina, MD — Voyager Therapeutics

Ralf Reilmann, MD, PhD — George Huntington Institute

Sarah Tabrizi, MBChB, PhD — University College London

Leslie Thompson, PhD — University of California Irvine

Huntington Study Group

Shari Kinel, JD — HSG Executive Director

Liz McCarthy, BA — HSG Director of Programs & Communications

Donna Moszkowicz — HSG Event Planner

Kristin Strazdins — HSG Accounting and Office Manager

Contributors

Meredith A. Achey, BM

Ryan E. Korn, BA

Lise Munsie, PhD

Publication Staff

Meredith A. Achey, BM — Deputy Editor

Ryan E. Korn, BA — Associate Editor

Robin Taylor — Production Editor

Martin Holmes — Technical Editor

David Kolko — Distribution Specialist

Related Post

Repair-HD

September 1, 2014 0
Human pluripotent stem cell differentiation, safety, and preparation for therapeutic transplantation in HD By: Christiane Dascher-Nadel, Anne Rosser, Stephen Dunnett…

HD Insights Volume 16 (PDF)

February 22, 2017 0
[pdf-embedder url=”http://huntingtonstudygroup.org/wp-content/uploads/2017/02/HD-Insights-Vol.-16-v.13-FINAL.pdf”] To read a non-PDF version of HD Insights Vol. 16, click here.

Meet the Scientist : Beverly Davidson

May 30, 2017 0
VITAL SIGNS NAME: Beverly Davidson, PhD TITLE: Chief Scientific Strategy Officer at the Children’s Hospital of Philadelphia (CHOP); Director of…